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ABSTRACT 
Background and Objectives: The aim of this study was to evaluate the outcomes of repeated percutaneous coro-
nary intervention (PCI) based on the restenosis pattern in drug-eluting stent (DES) failure. Subjects and Methods: 
From April 2003 to March 2006, all 67 patients (67 lesions) at our 3 centers who had DES in-stent restenosis (ISR) 
were enrolled. The patients were divided into 3 groups: group I had focal edge restenosis, group II had focal body 
restenosis, and group III had non-focal restenosis. All patients were treated with conventional PCI including 
plain old balloon angioplasty (POBA), cutting balloon angioplasty (CBA), and repeated DES implantation (Re-
DES). Angiographic and clinical one year follow-up results for the 3 groups were evaluated. Results: Sixteen pa-
tients were enrolled in group I, 36 in group II, and 15 in group III. Baseline clinical and angiographic characteristics 
and the proportion of patients in each group receiving each type of treatment strategy were not significantly dif-
ferent among the groups. Within each group, a comparison of angiographic and clinical outcomes for each thera-
peutic modality revealed that restenosis rates were not statistically different. Although rates of major adverse car-
diac events (MACE) were not statistically different between groups I and II, in group III, MACE were 3-fold higher 
for the POBA (4/4, 100.0%) and CBA (4/4, 100.0%) subgroups than for Re-DES (1/3, 33.3%) (p=0.06), but the 
differences did not reach statistical significance. Conclusion: The present study suggests that treatment of DES ISR 
should be individualized according to restenosis pattern: any PCI strategy appears appropriate for focal ISR patterns, 
while Re-DES might be a better choice for non-focal ISR patterns. (Korean Circ J 2009;39:408-413) 
 
KEY WORDS: Percutaneous transluminal coronary angioplasty; Restenosis; Drug-eluting stent; Coronary re-
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Introduction 
 
Although drug-eluting stents (DES) significantly re-
duce restenosis rates compared with bare-metal stents 
(BMS), treatment of coronary in-stent restenosis (ISR) 
remains a challenging problem. Much research has been 
devoted to the pathophysiology and treatment of ISR 
with DES; however, because of its relatively low inci-
dence, there is scant data on its management.
1) 
Studies have suggested a variety of possible treatment 
strategies using standard percutaneous coronary inter-
vention (PCI) techniques, including plain balloon an-
gioplasty (POBA), cutting balloon angioplasty (CBA), 
repeated DES implantation (Re-DES), radiation therapy, 
or local drug delivery.
2) Some studies reported that repeat-
ed PCI with DES, BMS, brachytherapy, POBA or CBA 
is safe and not associated with increased rates of vascular 
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complications.
3-6) Cosgrave et al.
7) suggested that Re-DES 
for DES restenosis is feasible and safe. In particular, si-
rolimus-eluting stent (SES) failure treated with traditio-
nal PCI yielded favorable outcomes, perhaps due to the 
predominantly focal nature of the SES restenotic lesion.
7)8) 
The use of DES for diffuse ISR is also feasible and safe.
9)10) 
Regardless of the therapeutic approach chosen, the 
pattern of restenosis itself is an important predictor of 
outcomes.
7) Similarly, in the era of DES implantation, 
the incidence of target-lesion revascularization (TLR) in-
creases with the pattern of restenosis treated.
11) Therefore, 
our study was done to evaluate real world outcomes for 
repeated PCI strategies according to the restenosis pat-
tern in DES failure. 
 
Subjects and Methods 
 
Study population 
We reviewed records for 1,465 patients (1,620 lesions) 
who underwent follow-up coronary angiogram (CAG) 
from among 2,540 patients who had undergone DES 
implantation in our 3 centers from April 2003 to March 
2006, and identified 83 patients (88 lesions) with DES 
ISR. Patients who were not treated for ISR or who had 
left main coronary artery lesions were excluded, and 67 
patients (67 lesions) with DES ISR were included in the 
final analyses. Coronary angiogram follow-up was plan-
ned for 9 months after ISR treatment for patients who 
had not experienced clinical events. 
Patients were divided into 3 groups according to res-
tenosis pattern. Group I had focal edge restenosis, Group 
II had focal body restenosis, and group III had non-
focal restenosis. All patients were treated with conventio-
nal PCI including POBA, CBA, and Re-DES. All pro-
cedures were performed using standard PCI techniques, 
and intravascular ultrasound (IVUS) imaging was used 
at the surgeon’s discretion. Coronary angiograms were 
obtained before and after the procedures, and at follow-
up, and they were analyzed by 2 independent angiogra-
phers. Angiographic and clinical follow-up {major ad-
verse cardiac events (MACEs)} results were evaluated for 
the 3 groups for 1 year. 
 
Definitions and outcome measures 
A focal lesion was defined as one with a length ≤10 
mm; non-focal lesions had lengths >10 mm. Edge res-
tenosis was defined as restenosis occurring within 5 mm 
at either side from and including the stent margin. Angio-
graphic restenosis was defined as diameter stenosis >50% 
by quantitative coronary angiography (QCA) within a 
previously stented segment (stent and 5 mm proximal 
and distal) at follow-up angiogram. TLR was defined as 
repeated revascularization secondary to a stenosis >50% 
within the stent or within the 5 mm borders proximal 
or distal to the stent edge. target-vessel revascularization 
(TVR) was defined as repeated revascularization of the 
target vessel. Myocardial infarction (MI) was diagnosed 
when cardiac creatinine kinase-MB levels were greater 
than three-fold the normal value, with chest pain lasting 
≥30 minutes or with the appearance of new electrocar-
diographic changes. All deaths were considered to be 
cardiac-related unless otherwise documented. A MACE 
was defined as death or MI and the need for TLR, TVR 
or coronary artery bypass graft (CABG). 
Coronary QCAs were analyzed using a validated edge 
detection system (CAAS II, Pie Medical Imaging, Maa-
stricht, The Netherlands). Minimal luminal diameter 
(MLD), reference vessel diameter (RD), and % diameter 
stenosis (DS) were measured at baseline, post-stenting, 
and at follow-up, respectively. 
 
Statistical analysis 
Continuous variables are presented as means±SD, 
and categorical variables as frequencies and percentages. 
Differences between groups in outcome variables were 
assessed using Pearson’s Chi-square test or Fisher’s exact 
test (whenever an expected cell value was <5) for catego-
rical data, and the Kruskal-W allis rank sum test and 
Wilcoxon rank sum test for continuous data. A p <0.05 
was considered to indicate a significant difference, and 
all reported p are 2-sided. Statistical analysis was per-
formed using SAS 9.1 (SAS Institute, Cary, NC, USA). 
 
Results 
 
Patients and baseline characteristics 
There were 16 focal edge restenotic lesions (group I), 
36 focal body restenotic lesions (group II), and 15 non-
focal restenotic lesions (group III). Angiographic success 
was achieved in all patients. Baseline clinical and angio-
graphic characteristics were similar among groups, except 
for hypertension, which was significantly more frequent 
in group III (p=0.03). Procedural anticoagulation and 
antiplatelet therapy was prescribed according to standard 
protocols. Medications prescribed after DES implanta-
tion included aspirin, clopidogrel, cilostazol, beta-bloc-
kers, angiotensin converting enzyme inhibitors (ACEI)/ 
angiotensin receptor blockers (ARB), and statins. Fre-
quencies of use of each medication were not significan-
tly different among groups (Table 1). 
Distribution of target vessels was not significantly dif-
ferent among groups, and the left anterior descending 
artery (LAD) was the most frequent target vessel. Mean 
stent length and diameter and proportions by type of 
inserted stents, i.e., SES or paclitaxel-eluting stent (PES), 
were not significantly different either (Table 2). 
 
Clinical and angiographic characteristics by percu-
taneous coronary intervention modality 
Mean follow-up duration was 10±5 months in group  
 
410·Treatment of In-Stent Restenosis After DES 
 
I, 10±8 months in group II and 16±13 months in 
group III (p=0.06). Acute myocardial infarction frequen-
cies were higher in group III (4, 26.7%) than in group I 
(2, 12.5%) or in group II (1, 2.8%) (p=0.02), and silent 
ischemia frequencies were higher in groups I (5, 31.2%) 
and II (13, 36.1%) than in group III (0, 0.0%) (p=0.02). 
The latter observation might be related to higher fre-
quencies of routine CAG follow-up in groups I and II 
than in group III. IVUS studies were done for 27 patients 
(40.3%), in which neointimal hyperplasia was the major 
cause of ISR. Stent fracture was seen in 1 (14.3%) case in 
group I, 8 (57.1%) in group II, and 2 (33.3%) in group 
III, but the incidence rates were not significantly dif-
ferent (p=0.20) (Table 3). 
Group III patients had longer mean lesion length and 
narrower pre-procedure MLD and pre-procedure % DS; 
however, this was related to grouping characteristics. 
POBA, CBA and Re-DES were done for the following 
numbers of patients (and the following percentages by 
groups): POBA (5, 31.3%), CBA (3, 18.8%), and Re-
DES (9, 56.3%) in group I; POBA (13, 36.1%), CBA 
(17, 47.2%), and Re-DES (6, 16.7%) in group II; and 
Table 1. Baseline clinical characteristics 
  Group I (n=16)  Group II (n=36)  Group III (n=15)  p
Age, years  58±8 60±9 64±10 0.25
Male sex (%)  19 (56.3)  29 (80.6)  10 (66.7)  0.18
Past medical history (%)         
Diabetes  19 (56.3)  18 (50.0)  14 (26.7)  0.23
Hypertension  11 (68.8)  15 (41.7)  12 (80.0)  0.03
Smoking   15 (31.3)  16 (44.4)  15 (33.3)  0.59
Hyperlipidemia  11 (68.8)  23 (63.9)  10 (66.7)  0.94
Old MI    13 (18.8)  16 (16.7)  0 (0.0)  0.22
Stroke   13 (18.8)  2 (5.6)  13 (20.0)  0.19
LVEF (%)  55±13 55±12 53±12 0.75
Medication after DES, n (%)         
Aspirin  16 (100.0)  36 (100.0)  15 (100.0)   
Clopidogrel  15 (93.8)  35 (97.2)  15 (100.0)  0.59
Cilostazol  11 (68.8)  22 (61.1)  15 (33.3)  0.11
Beta-blocker  12 (75.0)  25 (71.5)  10 (66.7)  0.87
ACEI/ARB  17 (43.7)  27 (75.0)  12 (80.0)  0.07
Statin  10 (62.5)  17 (47.2)  15 (33.3)  0.27
MI: myocardial infarction, LVEF: left ventricular ejection fraction, DES: drug-eluting stent, ACEI: angiotensin converting enzyme inhibitor, ARB:
angiotensin receptor blocker 
 
Table 2. Baseline angiographic characteristics of target lesions
  Group I (n=16)  Group II (n=36)  Group III (n=15)  p
Lesion characteristics, n (%)        0.15
Type A  1 (6.3)  20 (0.0)  10 (0.0)   
Type B1  5 (31.3)  24 (11.1)  12 (13.3)   
Type B2  2 (12.5)  25 (13.9)  12 (13.3)   
Type C  7 (43.8)  27 (75.0)  11 (73.3)   
IRA, n (%)  2 (12.5)  26 (16.7)  14 (26.7)  0.63
Target vessel         
LAD  8 (50.0)  19 (52.8)  7 (46.7)  0.94
LCX 2  (12.5)  16 (16.7)  2 (13.3)  1.00
RCA  6 (37.5)  11 (30.6)  7 (46.7)  0.52
Stent length (mm)  27±12 33±13 30±10 0.26
Stent diameter (mm)  3.0±0.3 3.0±0.3 3.0±0.2 0.69
Inserted stent, n (%)        0.19
SES  11 (68.8)  30 (83.3)  12 (80.0)   
PES  15 (31.3)  36 (16.7)  13 (20.0)   
Stent overlapping  13 (18.8)  39 (25.0)  12 (13.3)  0.73
IRA: infarct related artery, LAD: left anterior descending artery, LCX: left circumflex artery, RCA: right coronary artery, SES: sirolimus-
eluting stent, PES: paclitaxel-eluting stent 
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POBA (6, 25.0%), CBA (4, 26.7%), and Re-DES (5, 
33.3%) in group III. Frequencies of using treatment stra-
tegies were not different among groups (p=0.07) (Table 4). 
 
Angiographic and clinical outcomes at follow-up 
Angiographic follow-up was recommended nine mon-
ths after repeated PCI with the different therapeutic 
modalities, and clinical follow-up was planned for 1 
year. Anti-platelet medication (aspirin and clopidogrel) 
coverage was continued in all groups. Angiographic fol-
low-up was performed in 10 (62.5%) patients in group I, 
27 (75.0%) patients in group II, and 11 patients (73.3%) 
in group III (p=0.64); mean follow-up periods were 12
±9 months in group I, 10±5 months in group II, and 
8±3 months in group III (p=0.33). Restenosis was de-
tected in 3 (30.0%) patients in group I, in 10 (37.0%) in 
group II, and in 6 (54.5%) in group III, with no stati-
stically significant difference among proportions (p=0.48). 
A total 19 MACEs developed: 4 (40.0%) in Group I, 6 
(22.2%) in Group II and 9 (81.8%) in Group III. The 
rate of MACEs was significantly higher in group III 
than in groups I and II (p<0.01) (Table 5). 
Comparison of angiographic and clinical outcomes 
according to therapeutic modality revealed that restenosis 
Table 3. Clinical characteristics determining PCI modalities
  Group I (n=16)  Group II (n=36)  Group III (n=15)  p 
Diagnosis at first TLR, n (%)         
Stable angina  7 (43.8)  18 (50.0)  9 (60.0)  0.68
Unstable angina  2 (12.5)  14 (11.1)  2 (13.3)  1.00
Acute MI  2 (12.5)  1 (2.8)  4 (26.7)  0.02
Silent ischemia  5 (31.2)  13 (36.1)  0 (0.0)  0.02
Follow up duration, months  10±5 10±8 16±13 0.06
IVUS, n (%)  7 (43.8)  14 (38.9)  6 (40.0)  0.95
Neointimal hyperplasia  6 (85.7)  16 (42.9)  4 (66.7)  0.20
Stent fracture  1 (14.3)  18 (57.1)  2 (33.3)  0.20
Stent recoil  0 (0.0)  10 (0.0)  0 (0.0)   
TLR: target-lesion revascularization, MI: myocardial infarction, IVUS: intra vascular ultrasound, PCI: percutaneous coronary intervention
 
Table 4. Angiographic findings by PCI modality for ISR treatment
  Group I (n=16)  Group II (n=36)  Group III (n=15)  p 
Lesion length (mm)  11.5±6.0 11.2±5.8 23.3±8.8  <0.01
RD (mm)  3.1±0.4 3.0±0.5 3.0±0.2  <0.56
Pre-procedure MLD (mm)  0.38±0.20 0.54±0.33 0.17±0.15  <0.01
Post-procedure MLD (mm)  2.63±0.69 2.65±0.47 2.71±0.32  <0.92
Pre-procedure DS (%)  88±9 81±11 94±5  <0.01
Post-procedure DS (%)  23±16 17±11 13±10  <0.31
Treatment strategies        <0.07
POBA, n (%)  5 (31.3)  13 (36.1)  6 (25.0)   
CBA, n (%)  3 (18.8)  17 (47.2)  4 (26.7)   
Re-DES, n (%)  9 (56.3)  16 (16.7)  5 (33.3)   
RD: reference diameter, MLD: minimal luminal diameter, DS: diameter stenosis, POBA: plain old balloon angioplasty, CBA: cutting balloon
angioplasty, Re-DES: repeated drug-eluting stent implantation, PCI: percutaneous coronary intervention, ISR: instent restenosis 
 
Table 5. Angiographic and clinical outcomes at follow-up
  Group I (n=16)  Group II (n=36)  Group III (n=15)  p
F/U rate of CAG, n (%)  10 (62.5)  27 (75.0)  11 (73.3)  <0.64
F/U duration, months  12±9 10±5 8±3  <0.33
Restenosis rate, n (%)  3 (30.0)  10 (37.0)  6 (54.5)  <0.48
MACE rate, n (%)  4 (40.0)  16 (22.2)  9 (81.8)  <0.01
Death, n (%)  0 (0.0)  1 (3.7)  2 (18.2)   
TLR, n (%)  3 (30.0)  15 (18.5)  6 (54.5)   
TVR, n (%)  0 (0.0)  0 (0.0)  1 (9.1)   
CABG, n (%)  1 (10.0)  0 (0.0)  0 (0.0)   
MI, n (%)  0 (0.0)  0 (0.0)  0 (0.0)   
F/U: follow up, CAG: coronary angiogram, MACE: major adverse cardiac event, TLR: target-lesion revascularization, TVR: target-vessel revascu-
larization, CABG: coronary artery bypass graft, MI: myocardial infarction 
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rates were not different according to therapeutic moda-
lities within each group. Restenosis rates were as follows: 
in group I, POBA (1/3, 33.3%), CBA (1/1, 100.0%), and 
Re-DES (1/6, 16.7%) (p=0.46); in group II, POBA (4/ 
12, 33.3%), CBA (4/10, 40.0%), and Re-DES (2/5, 
40.0%) (p=1.00); and in group III, POBA (3/4, 75.0%), 
CBA (3/4, 75.0%), and Re-DES (0/3, 0.0%) (p=0.14). 
There was no statistically significant difference in MACE 
rates between groups I and II. MACE rates were as fol-
lows: in group I, POBA (2/3, 66.7%), CBA (1/1, 100.0%), 
and Re-DES (1/6, 16.7%) (p=0.19); and in group II, 
POBA  (3/12, 25.0%), CBA (2/10, 20.0%), and Re-
DES (1/5, 20.0%) (p=1.00). However, in group III, 
MACE rates were relatively higher for POBA (4/4, 
100.0%) and CBA (4/4, 100.0%) than for Re-DES (1/3, 
33.3%) (p=0.06), but these differences did not reach 
statistical significance (Table 6). 
 
Discussion 
 
The main findings of this study are as follows: 1) re-
stenosis rates were not significantly different between 
focal (edge and body restenosis) and non-focal ISR; 2) 
restenosis rates were not significantly different among 
focal edge, focal body and non-focal ISR lesions regardless 
of the therapeutic modality chosen (POBA, CBA, and 
Re-DES); and 3) for non-focal ISR lesions, POBA and 
CBA strategies might be associated with higher MACE 
rates, and Re-DES might be a better choice for the le-
sions. 
Although ISR after DES implantation is much less 
frequent than after BMS, it is not less puzzling. Mole-
cular mechanisms of arterial remodeling are less well 
understood and insight into the mechanisms of DES 
failure is still limited. It appears that the causes of res-
tenosis after implantation of BMS and DES are funda-
mentally the same. Restenosis is the arterial wall’s healing 
response to mechanical injury and includes two main 
processes: neointimal hyperplasia and vessel remodeling.
1) 
Neointimal proliferation is the principal mechanism un-
derlying ISR, and it is the result of endothelial damage 
after stent expansion.
12-14) In our study, IVUS was per-
formed in 27 cases (40.3%), and neointimal hyperplasia 
was the main cause with stent fracture also being appa-
rent in a total of 11 cases (40.7%). Although some reports 
have suggested that stent fracture might be another po-
tential risk factor for restenosis, in our study the risk 
was not significantly elevated; however, there might have 
been some selection bias, and stent fracture might still 
be considered as another potential risk factor of ISR.
15)16) 
The patterns of angiographic restenosis after BMS 
implantation have been previously described, and it was 
shown that the Mehran ISR classification is an inde-
pendent predictor of TLR, emphasizing the prognostic 
relevance of angiographic features after stent failure. 
Mehran et al.
17) showed that at 1-year follow-up in pa-
tients undergoing percutaneous coronary intervention 
for BMS ISR, a significantly higher rate of TLR occur-
red with more complex levels of ISR classification. Sim-
ilarly, in the era of DES implantation, the incidence of 
TLR increases with the pattern of restenosis treated.
11) 
In the present study, restenosis rates were not different 
among groups but MACE rates were numerically high-
er in group III due to the high TLR rate. This result was 
comparable with that of a previous study. 
Currently, there is a paucity of published data on the 
optimal management of DES restenosis. Some investi-
gators have reported that repeated PCI with DES, BMS, 
brachytherapy, POBA, or CBA was safe and did not in-
crease rates of vascular complications.
2-7)18)19) Most reports 
on DES restenosis have indicated that the majority of 
cases, particularly those after SES implantation, are focal. 
SES failure treated with traditional percutaneous coro-
nary intervention yielded good outcomes at 1-year fol-
low-up (a secondary failure rate of only 23%), perhaps 
due to the predominantly focal nature of the SES reste-
notic lesion.
8) Systematic use of SES to treat ISR was safe 
and effective in an unselected series of consecutive pati-
ents treated in a real-world scenario, providing very low 
9-month ischemia-driven TLR and MACE rates.
20) On 
the basis of BMS-controlled RCT data, there is a definite 
therapeutic advantage associated with SES and PES use 
for the prevention of ISR. SES and PES continued to 
exceed the therapeutic potential of BMS, with a slight 
but consistent angiographic advantage being observed 
with SES.
4)13)21) Furthermore, the use of DES for diffuse 
Table 6. Angiographic and clinical outcomes by therapeutic modality
  POBA  CBA  Re-DES  p
Restenosis  rate       
Group I (n=10) (%)  1/3 (33.3)  1/1 (100.0)  1/6 (16.7)  0.46
Group II (n=27) (%)  4/12 (33.3)  4/10 (40.0)  2/5 (40.0)  1.00
Group III (n=11) (%)  3/4 (75.0)  3/4 (75.0)  0/3 (0.0)  0.14
MACE  rate       
Group I (n=10) (%)  2/3 (66.7)  1/1 (100.0)  1/6 (16.7)  0.19
Group II (n=27) (%)  3/12 (25.0)  2/10 (20.0)  1/5 (20.0)  1.00
Group III (n=11) (%)  4/4 (100.0)  4/4 (100.0)  1/3 (33.3)  0.06
POBA: plain old balloon angioplasty, CBA: cutting balloon angioplasty, Re-DES: repeated drug-eluting stent implantation 
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ISR is feasible and safe, and is associated with acceptable 
early and mid-term results.
9)10)20-22) On the other hand, 
Albiero et al.
18) suggested that CBA and traditional PT-
CA are equally effective in preventing ISR recurrence. 
In our study, restenosis rates according to therapeu-
tic modality were not significantly different within each 
group, and MACE rates were not different between the 
focal edge and focal body lesion groups. But, even if dif-
ferences did not reach statistical significance due to re-
latively small sample sizes, MACE rates were relatively 
higher for POBA and CBA than for Re-DES for non-
focal lesions. Based on our results, it appears that all PCI 
options are associated with favorable outcomes when 
used for focal restenotic lesions, while Re-DES appears 
to be associated with more favorable clinical outcomes 
for non-focal lesions. 
Limitations of this study is that: the data were collected 
in a retrospective and nonrandomized manner; the sam-
ple size was small; there was a relatively low rate of an-
giographic follow-up. A large scale randomized clinical 
trial is warranted to determine the optimal strategy for 
the treatment of ISR after DES implantation. 
In conclusion, treatment of DES ISR should be indi-
vidualized according to restenosis pattern, with all PCI 
strategies appearing appropriate for focal ISR patterns, 
and Re-DES appearing to be a better choice for non-fo-
cal ISR patterns. 
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